Feb. 27, 2025 — Perovskite solar cells could last ten times longer thanks to new research, which suggests alumina nanoparticles significantly enhance the lifespan and stability of these high ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

Class actions are gaining momentum in the food and beverage sector, according to Law.com Radar. The platform surfaced 24 ...

Meanwhile, the Claude Code has been an early product but has been an asset for test-driven development, debugging complex ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to Novo Nordisk's Wegovy and Ozempic weight-loss drugs. Hims stock stood ...

So you shouldn't have to put up with poor service. Our annual energy satisfaction survey covers 16 suppliers in Great Britain. Our most recent results were published in January 2025 based on nearly 12 ...

Researchers have developed a method that is 100 times faster and therefore much more energy efficient. Instead of ...

Drug compounders are suing the Food and Drug Administration for improperly declaring an end to the shortage of Novo Nordisk’s weight-loss and diabetes drugs, accusing the agency of “depriving patients ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk’s NOVO.B-3.02%decrease; red down pointing triangle weight-loss medications Wegovy and Ozempic has been resolved ...

The FDA today declared the national deficit of GLP-1 diet drugs at an end. Well, at least for Novo Nordisk's Ozempic and Wegovy. Novo Nordisk sales should be going up, and Hims & Hers Health's ...

Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly. So, sales of Ozempic and Wegovy amounted to DKK 53.7 billion in the fourth quarter of 2024, increasing by ...